|
11 Jun 2020 |
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy
|
|
10 Jun 2020 |
Twist Bioscience Partners with Serimmune to Identify SARS-CoV-2 Therapeutic Antibody Candidates
|
|
10 Jun 2020 |
Opthea Reports Positive Phase 2a Trial Results of OPT-302 in Diabetic Macular Edema
|
|
10 Jun 2020 |
Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody
|
|
10 Jun 2020 |
Tychan to Begin First Clinical Trials for First Novel Monoclonal Antibody Against COVID-19
|
|
10 Jun 2020 |
Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Disease Activity in Phase 2a Study of Patients with Rheumatoid Arthritis
|
|
10 Jun 2020 |
AbbVie and Genmab Announce Broad Oncology Collaboration
|
|
10 Jun 2020 |
Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody
|
|
10 Jun 2020 |
Lyvgen Announces Clinical Trial Collaboration With MSD
|
|
10 Jun 2020 |
Vanderbilt, AstraZeneca sign new COVID-19 antibody agreement
|
|
10 Jun 2020 |
Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma
|
|
09 Jun 2020 |
Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies
|
|
09 Jun 2020 |
Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer
|
|
09 Jun 2020 |
IGY Life Sciences Partners with MMS Holdings to Develop Novel COVID-19 Antibody Treatment
|
|
08 Jun 2020 |
Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial
|
|
08 Jun 2020 |
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program
|
|
08 Jun 2020 |
Alpine Immune Sciences Provides Clinical Update of its Phase 1 Trial of ALPN-101 in Healthy Volunteers at the European League Against Rheumatism (EULAR) E-Congress 2020
|
|
08 Jun 2020 |
Heat Biologics Announces FDA Clearance of Investigational New Drug (IND) Application for PTX-35
|
|
08 Jun 2020 |
Junshi Biosciences Announces Dosing of First Healthy Volunteer in Phase I Clinical Study of SARS-CoV-2 Neutralizing Antibody JS016 in China
|
|
08 Jun 2020 |
CSL Behring Presents Results for Garadacimab as Preventive Treatment in Hereditary Angioedema
|
|
07 Jun 2020 |
Celldex’s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase—an Indicator of Mast Cell Burden—and a Favorable Safety Profile
|
|
06 Jun 2020 |
AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19
|
|
05 Jun 2020 |
Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
|
|
05 Jun 2020 |
Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept
|
|
05 Jun 2020 |
Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases at the European Congress of Rheumatology E-Congress 2020
|
